Results 61 to 70 of about 7,453,211 (372)

Pathways Across the Valley of Death: Novel Intellectual Property Strategies for Accelerated Drug Discovery [PDF]

, 2008
Drug discovery is stagnating. Government agencies, industry analysts, and industry scientists have all noted that, despite significant increases in pharmaceutical R&D funding, the production of fundamentally new drugs - particularly drugs that work on ...
Crossman, Colin, Rai, Arti K., Reichman, Jerome H., Uhlir, Paul F.   +3 more
core   +1 more source

Identification of novel small molecule inhibitors of ETS transcription factors

FEBS Letters, EarlyView.
ETS transcription factors play an essential role in tumourigenesis and are indispensable for sprouting angiogenesis, a hallmark of cancer, which fuels tumour expansion and dissemination. Thus, targeting ETS transcription factor function could represent an effective, multifaceted strategy to block tumour growth. The evolutionarily conserved E‐Twenty‐Six
Shaima Abdalla, Zary Forghany, Jin Ma, Johan G. Hollander, Ruta Nachane, Karoly Szuhai, Pancras C. W. Hogendoorn, Peter ten Dijke, Dipen Shah, David A. Baker   +9 more
wiley   +1 more source

WORKPLACE SUBSTANCE USE, THE RISK OF OCCUPATIONAL INJURY, AND TESTING [PDF]

, 2005
Over the past 20 years, the "workplace substance abuse prevention industry" has grown enormously in size and has become more sophisticated in its marketing approach. Drug testing alone has become a $6 billion industry.
Zimbardi, Guy
core  

Spot‐14 and its paralog Spot‐14R regulate expression of metabolic and thermogenic pathway genes in murine brown and beige adipocytes

FEBS Letters, EarlyView.
Spot‐14 and Spot‐14R play distinct roles in regulating metabolism in brown and beige adipocytes. While both influence lipid and glucose pathways, Spot‐14 uniquely controls thermogenic gene expression. This dual regulation balances energy storage and heat production, highlighting potential therapeutic targets for obesity and metabolic disorders. Spot 14
Lidia Itzel Castro‐Rodríguez, Cristina Velez‐delValle, Claudia Patricia Hernández‐Mosqueira, Walid Kuri‐Harcuch   +3 more
wiley   +1 more source

Evaluation of Biological Mechanisms of Quanduzhong Capsule for Treating Osteoporosis by Integrating Untargeted Metabolomics and Network Pharmacology

Pharmaceutical Fronts, 2023
Osteoporosis (OP) is a metabolic disease characterized by bone formation and resorption disturbances. Quanduzhong Capsule (QDZC) is a common treatment for OP in China; however, the effective components and metabolites of the drug after oral ...
Fang-Fang Yu, Le-Yi Huang, Man-Man Li, Shi-Wen Cui, Jie Yuan, Xiao-Feng Li, Tong Wu   +6 more
doaj   +1 more source

Willful Misconduct: How Bill Frist and the Drug Lobby Covertly Bagged a Liability Shield [PDF]

, 2006
Drug industry lobbyists conspired with the White House and Senate Majority Leader Bill Frist (R-Tenn.) last year to craft a sweeping liability provision that shields the industry from lawsuits over products used to treat pandemic illnesses, even in cases
John O'Donnell
core  

The Effects of Industry Sponsorship on Comparator Selection in Trial Registrations for Neuropsychiatric Conditions in Children [PDF]

, 2013
Pediatric populations continue to be understudied in clinical drug trials despite the increasing use of pharmacotherapy in children, particularly with psychotropic drugs.
Bourgeois, Florence T., Coiera, Enrico, Dunn, Adam G., Mandl, Kenneth D.   +3 more
core   +3 more sources

Modifications in FLAP's second cytosolic loop influence 5‐LOX interaction, inhibitor binding, and leukotriene formation

FEBS Letters, EarlyView.
The enzyme 5‐lipoxygenase (5‐LOX) catalyzes the first step in the biosynthesis of leukotrienes (LTs) involved in inflammatory pathophysiology. After cellular stimulation, 5‐LOX translocates to the nucleus, interacting with the 5‐LOX‐activating protein (FLAP) to form LTA4 from arachidonic acid (AA).
Erik Romp, Katharina Rataj, Stefanie König, Marcia E. Newcomer, Oliver Werz, Ulrike Garscha   +5 more
wiley   +1 more source

The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules

Molecules
With the COVID-19 pandemic behind us, the U.S. Food and Drug Administration (FDA) has approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average).
B. G. de la Torre, Fernando Albericio
semanticscholar   +1 more source

Industry-scale application and evaluation of deep learning for drug target prediction [PDF]

, 2019
Artificial intelligence (AI) is undergoing a revolution thanks to the breakthroughs of machine learning algorithms in computer vision, speech recognition, natural language processing and generative modelling.
Ashby, Thomas J., Böhm, Stanislav, Ceulemans, Hugo, Chen, Hongming, Chupakhin, Vladimir, Cima, Vojtěch, Engkvist, Ola, Golib-Dzib, Jose-Felipe, Greene, Nigel, Hochreiter, Sepp, Jeliazkova, Nina, Klambauer, Günter, Martinovič, Jan, Mayr, Andreas, Sturm, Noe, Van, Thanh Le, Vander Aa, Tom, Vandriessche, Yves, Wegner, Joerg   +18 more
core   +2 more sources